I normally don’t talk about individual companies (outside of that car company), let alone biotech companies. But this post is a bit different. Normally I wouldn’t post a biotech report to my blog but unfortunately, I’m not very good at the ‘internets’. And I was having trouble uploading our biotech report to various open source websites like SCRIBD or DocuHub and then I recalled, that a few years ago I was able to publish some of my late Grandfather’s work to this blog. If you haven’t read that blog post or my Grandfather’s writings, I highly recommend that you do. He was great man and I don’t know how to say this but he was kind of a big deal (he’s the guy in the Speedo)…

Anyways here we are. You were expecting a new and prescient macro thesis (JK, I know I’m your best contra), and instead you get a report on biotech company you’ve never heard of. If you are not interested in the incredibly risky area of biotech that’s fine. This report is not for you. I expect it won’t be for most. The main goal of this post, is to publicize our views on a specific, small cap Canadian biotech company called Antibe Therapeutics (ATBPF).

The link to the report can be found below the Executive Summary:

“Non-Steroid Anti-Inflammatory Drugs (NSAIDs) are some of the most commonly prescribed drugs in the world. Despite their popularity, these drugs come with a number of serious side effects. Every year in the US, approximately 100,000 people are hospitalized and more than 16,000 die due to the gastrointestinal (GI) side effects of NSAIDs alone. In the elderly, the cost associated with GI related toxicity associated from NSAIDs exceeds $4B annually. We believe Antibe Therapeutics (ATBPF, ATE.V) has found a solution to this problem. By attaching a Hydrogen Sulfide (H2S) releasing moiety to Naproxen, Antibe was able to create an NSAID, ATB-346, that not only possesses a drastically reduced GI toxicity profile, but is also more effective at relieving pain and inflammation than other NSAIDs. While the potency of ATB-346 has yet to be proved, it will be soon. Antibe has just completed dosing its phase 2b efficacy study for patients with osteoarthritis. Data from this important study is due by the end of April. This report consists of two parts: the data Antibe has generated thus far which support our claim that the company has developed a safe and effective NSAID and our scientific research that supports the company’s data.”

Report Link: Antibe Therapeutics: The Next Generation of NSAIDs